HEOR / HTA / Market Access
HEOR / HTA / Market Access
I specialize in HTA / HEOR / Market Access support for medical technologies (drugs, gene therapies, devices, diagnostic tests) in Switzerland. I would be happy to discuss your needs.
Experience
- Since 2024 - Founder, Elibo Health LLC
- 2022-23 - Principal, Value & Payer Evidence, IQVIA (EMEA)
- 2020-22 - Senior Consultant Market Access Switzerland/ Health Economics Europe. HealthEcon AG, Basel, Switzerland
- 2004-2020 - Responsible for projects covering HTA/ HEOR/ Market Access Switzerland (BAG, BSV), Germany (G-BA, IQWiG, InEK), UK (NICE), Sweden (TLV). HealthEcon AG, Basel, Switzerland
Skills
- Responsible for Swiss reimbursement applications, including strategy, dossier and price negotiations
- Development and communication of evidence-based value messages regarding efficacy/ effectiveness, usefulness and economic efficiency (Swiss WZW criteria)
- Systematic & targeted literature reviews
- Economic models & studies
- AdBoards
- Languages: German (native), English (quasi-native), French & Italian (both fluent if not perfect)
Education
- PhD Health Economics, University of St Andrews, UK
- MA (Jt. Hons) Economics - Management, University of St. Andrews, UK
Selected Publications
- Brock et al. Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) and Iron Deficiency in Switzerland. PharmacoEconomics – Open 2022; 6: 735-743
- Moradi-Lakeh, et al. Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland. Adv Ther 2021; 38: 3427-3443